Traduction de «risk of breast cancer with oral contraceptive use in women » (Français → Néerlandais) :

D’après D.M. Grabrick et al.: Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer.
Naar D.M. Grabrick et al.: Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer.

drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States
compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ

Risk of non-fatal venous thromboembolism in women using oral contraceptives containing
Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone

Use of combined oral contraceptives among women with
Use of combined oral contraceptives among women with migraine and

(Narod 2002) Narod SA, Dubé MP, Klijn J et al. Oral Contraceptives and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation
(Narod 2002) Narod SA, Dubé MP, Klijn J et al. Oral Contraceptives and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. J Natl

Table 10: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS (Sweden) 0,93 (0,63-1,36) 0,86 (0,75-0,99) Edinburgh (UK) 0,75 (0.48-1,18) 0,85 (0,75-0,97)
Table 8: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS (Sweden) 0,93 (0,63-1,36) 0,86 (0,75-0,99) Edinburgh (UK) 0,75 (0.48-1,18) 0,85 (0,75-0,97)